Literature DB >> 24664424

Immediate radical therapy or conservative treatments when meeting the Milan criteria for advanced HCC patients after successful TACE.

L Jiang1, J Y Lei, W T Wang, L N Yan, B Li, T F Wen, M Q Xu, J Y Yang, Y G Wei.   

Abstract

BACKGROUND AND AIMS: Many advanced hepatocellular carcinoma (HCC) cases can be successfully downstaged into the Milan criteria; however, immediate radical therapy cannot be applied to all such patients for various reasons. Of the patients who are not eligible for immediate radical therapy, some accept repeated downstaging therapies and some undergo persistent observation. The aim of the present study was to compare long-term survival between these two groups of patients. PATIENTS AND METHODS: Between August 2003 and October 2008, 156 HCC patients successfully received downstaging therapy resulting in compliance with the Milan criteria. Of those, 98 cases accepted radical therapies, including liver transplantation (LT), resection, or radiofrequency ablation (RFA) (group 1), and 58 cases underwent repeated transcatheter arterial chemoembolization (TACE) or persistent observation (group 2). The baseline characteristics, demographic data, downstaging protocol, and information on long-term outcomes were collected and compared.
RESULTS: No significant differences were observed in the patient demographic data, downstaging protocols, or tumor characteristics between the two groups. The 1-, 3-, and 5-year overall survival rates were 92.9, 82.7, and 78.6 %, respectively, in group 1, whereas these rates were 82.8, 65.5, and 48.3 %, respectively, in group 2 (P = 0.046). Among the 58 patients in group 2, the 1-, 3-, and 5-year overall survival rates were 92.3, 65.4, and 46.2 %, respectively, in the repeated TACE group, and 81.3, 65.6, and 50 %, respectively, in the persistent observation group (P = 0.783).
CONCLUSION: Immediate radical therapy should be the first choice for advanced HCC patients who undergo successful TACE, and repeated TACE is unnecessary.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24664424     DOI: 10.1007/s11605-014-2508-2

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  28 in total

1.  Patients with unresectable hepatocellular carcinoma beyond Milan criteria: should we perform transarterial chemoembolization or liver transplantation?

Authors:  J M Kim; C H D Kwon; J-W Joh; S J Kim; M Shin; E Y Kim; J I Moon; G O Jung; G-S Choi; S-K Lee
Journal:  Transplant Proc       Date:  2010-04       Impact factor: 1.066

Review 2.  The changing pattern of epidemiology in hepatocellular carcinoma.

Authors:  Helena Nordenstedt; Donna L White; Hashem B El-Serag
Journal:  Dig Liver Dis       Date:  2010-07       Impact factor: 4.088

3.  The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma.

Authors:  Francis Y Yao; Milan Kinkhabwala; Jeanne M LaBerge; Nathan M Bass; Robert Brown; Robert Kerlan; Alan Venook; Nancy L Ascher; Jean C Emond; John P Roberts
Journal:  Am J Transplant       Date:  2005-04       Impact factor: 8.086

4.  Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy.

Authors:  Jian-Yong Lei; Lu-Nan Yan; Wen-Tao Wang
Journal:  World J Gastroenterol       Date:  2013-07-21       Impact factor: 5.742

5.  Surgical resection versus open-approach radiofrequency ablation for small hepatocellular carcinomas within Milan criteria after successful transcatheter arterial chemoembolization.

Authors:  Jianyong Lei; Wentao Wang; Lunan Yan
Journal:  J Gastrointest Surg       Date:  2013-10       Impact factor: 3.452

6.  How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE?

Authors:  Gerd Otto; Marcus Schuchmann; Maria Hoppe-Lotichius; Michael Heise; Arndt Weinmann; Torsten Hansen; Michael P Pitton
Journal:  J Hepatol       Date:  2013-04-12       Impact factor: 25.083

7.  Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma.

Authors:  Mauricio Silva; Angel Moya; Marina Berenguer; Fernando Sanjuan; Rafael López-Andujar; Eugenia Pareja; Rodrigo Torres-Quevedo; Victoria Aguilera; Eva Montalva; Manuel De Juan; Angelo Mattos; Martín Prieto; José Mir
Journal:  Liver Transpl       Date:  2008-10       Impact factor: 5.799

8.  Downstaging advanced hepatocellular carcinoma to the Milan criteria may provide a comparable outcome to conventional Milan criteria.

Authors:  Jianyong Lei; Wentao Wang; Lunan Yan
Journal:  J Gastrointest Surg       Date:  2013-05-30       Impact factor: 3.452

9.  Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis.

Authors:  Francis Y Yao; Robert K Kerlan; Ryutaro Hirose; Timothy J Davern; Nathan M Bass; Sandy Feng; Marion Peters; Norah Terrault; Chris E Freise; Nancy L Ascher; John P Roberts
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

10.  Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation.

Authors:  William C Chapman; M B Majella Doyle; Jourdan E Stuart; Neeta Vachharajani; Jeffrey S Crippin; Christopher D Anderson; Jeffrey A Lowell; Surendra Shenoy; Michael D Darcy; Daniel B Brown
Journal:  Ann Surg       Date:  2008-10       Impact factor: 12.969

View more
  3 in total

1.  In vitro comparative study of drug loading and delivery properties of bioresorbable microspheres and LC bead.

Authors:  Lihui Weng; Hsiang-Jer Tseng; Parinaz Rostamzadeh; Jafar Golzarian
Journal:  J Mater Sci Mater Med       Date:  2016-10-17       Impact factor: 3.896

2.  Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma.

Authors:  Lei Jianyong; Zhong Jinjing; Yan Lunan; Zhu Jingqiang; Wang Wentao; Zeng Yong; Li Bo; Wen Tianfu; Yang Jiaying
Journal:  Sci Rep       Date:  2017-02-03       Impact factor: 4.379

Review 3.  Compliance with ethical standards in the reporting of donor sources and ethics review in peer-reviewed publications involving organ transplantation in China: a scoping review.

Authors:  Wendy Rogers; Matthew P Robertson; Angela Ballantyne; Brette Blakely; Ruby Catsanos; Robyn Clay-Williams; Maria Fiatarone Singh
Journal:  BMJ Open       Date:  2019-02-05       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.